Chronic Remote Ischemic Preconditioning as a Complement to Conventional Prenatal Care for Preeclampsia
NCT ID: NCT05564988
Last Updated: 2022-10-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
58 participants
INTERVENTIONAL
2022-10-31
2026-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Our research project aims to study the effect of preconditioning on blood pressure.
Preconditioning consists of using a blood pressure cuff and inflating it on the upper limb -like during a standard blood pressure measurement- for several minutes followed by a rest period in order to create "ischemia-reperfusion" periods. This technique would allow the release of beneficial substances into the bloodstream that would lower blood pressure. This method has been used for several years in different specialties and has produced good results on the heart, kidneys, lungs and brain.
With this technique we hope to stabilize or even reduce blood pressure in cases of pre-eclampsia and thus prolong the pregnancy.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of Cardiovascular Risk After Preeclampsia in General Practitioners and Patients
NCT06059937
Balance of Angiotensin II Receptors in Vessel Function After Preeclampsia
NCT06157580
Sensitivity of Angiotensin II Type II Receptors in Women Following Preeclampsia
NCT05937841
First-trimester Prediction of Preeclampsia
NCT02189148
Prospective Study in Pregnant Women With Hypercoagulopathy
NCT00215969
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Preconditionning
Ischemia will be obtained after inflating the cuff to a pressure of 200 mmHg (or a pressure at least 50 mmHg above the patient's systolic pressure). After a five-minute period, the cuff will be deflated and the arm allowed to reperfuse for five minutes. These maneuvers will be repeated until 3 cycles of ischemia- reperfusion have been completed once a day. Patients will experiment with this procedure for at least 5 days.
Preconditionning
Remote ischemic conditioning will be induced using a Tourniquet cuff applied to the patient's non-dominant arm. The device used will be an Ulrich Kariba machine. A strip of absorbent cotton will be applied to the arm and the tension cuff will be placed over it in a standard way. The systolic pressure and the application time will be set manually.
Ischemia will be obtained after inflating the cuff to a pressure of 200 mmHg (or a pressure at least 50 mmHg above the patient's systolic pressure). After a five-minute period, the cuff will be deflated and the arm allowed to reperfuse for five minutes. These maneuvers will be repeated until 3 cycles of ischemia- reperfusion have been completed once a day. Patients will experiment with this procedure for at least 5 days.
Control
For subjects assigned to the control group, the pneumatic cuff is placed around the upper arm, and inflation of a blood pressure to a lower pressure (50mmHg) which will result in no impairment of antegrade flow.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Preconditionning
Remote ischemic conditioning will be induced using a Tourniquet cuff applied to the patient's non-dominant arm. The device used will be an Ulrich Kariba machine. A strip of absorbent cotton will be applied to the arm and the tension cuff will be placed over it in a standard way. The systolic pressure and the application time will be set manually.
Ischemia will be obtained after inflating the cuff to a pressure of 200 mmHg (or a pressure at least 50 mmHg above the patient's systolic pressure). After a five-minute period, the cuff will be deflated and the arm allowed to reperfuse for five minutes. These maneuvers will be repeated until 3 cycles of ischemia- reperfusion have been completed once a day. Patients will experiment with this procedure for at least 5 days.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Gestational age between 24 0/7 and 36 6/7 weeks' gestation
* Hospitalization for non-severe pre-eclampsia (non-severe hypertension = Systolic blood pressure between 140 and 160mmHg, diastolic blood pressure between 90 and 110mmHg associated with one of these: proteinuria \>=300mg/24h/thrombocytopenia 100-150G/L/central symptoms such as headache responding to standard analgesics/hyperreflexia without clonus/decreased fibrinogen/haptoglobin \<0.1/utero-placental dysfunction with IUGR and/or umbilical Doppler Class II)
* Maternal age \>18 years
* Good comprehension of French allowing easy understanding of the information protocol and the consent form
Exclusion Criteria
* Renal disease
* Pre-pregnancy diabetes
* Autoimmune disease (SAPL, SLE, Sjögren)
* Severe PE (Systolic blood pressure \>160mmHg, diastolic blood pressure \>140mmHg, hepatic cytolysis at twice the norm, right hypochondrium or epigastric pain, central symptoms such as clonus or headache resistant to usual treatment or disturbed consciousness, thrombocytopenia \<100G/L, acute pulmonary edema, renal failure defined by doubling of baseline creatinine value or creatinine \>97 micromol/L)
* Suspected fetal anomaly or malformation
* HELLP syndrome
* Eclampsia attack
* Pathological fetal monitoring
* Known maternal upper limb vascular anomaly
* Severe maternal cardiac pathology
* Maternal history of deep vein thrombosis of the upper limb
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
DAVID DESSEAUVE
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
DAVID DESSEAUVE
Head of delivery room
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hélène Legardeur
Role: PRINCIPAL_INVESTIGATOR
CHUV
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2021-01516
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.